Sachiko Tanaka

Sachiko Tanaka

Auto-generated profile, based on publicly available information

Sachiko Tanaka

Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012
Verified
Journal Article
Closed access
KOKenji Onda
Kenji Onda
RSRieko Suzuki
Rieko Suzuki
STSachiko Tanaka
Sachiko Tanaka
HOHirokazu Oga
Hirokazu Oga
KOKitaro Oka
Kitaro Oka
俊平俊 彦 平野
俊 彦 平野

1 March 2009 in International Immunopharmacology
Verified
Journal Article
Closed access
STSachiko Tanaka
Sachiko Tanaka
MMMasayuki Masuda
Masayuki Masuda
KNKanako Nakajima
Kanako Nakajima
NINobuhiro Ido
Nobuhiro Ido
TOTakao Ohtsuka
Takao Ohtsuka
THToshihiko Hirano
Toshihiko Hirano

1 January 2007 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Closed access
PDF file
STSachiko Tanaka
Sachiko Tanaka
THToshihiko Hirano
Toshihiko Hirano
TSToyokazu Saito
Toyokazu Saito
NWNobuo Wakata
Nobuo Wakata
KOKitaro Oka
Kitaro Oka
Tacrolimus hydrate (FK506) reduces the symptoms of myasthenia gravis (MG) due to its immunosuppressive properties. A drug efflux pump P-glycoprotein (P-gp) actively transports FK506 out of target cells, thereby reducing their efficacy. We investigated the influence of FK506 therapy on the P-gp function of peripheral-blood mononuclear cells (PBMCs) in MG patients. Six MG patients treated with FK506 (MG(FK+)), four MG patients treated without FK506 administration (MG(FK−)), and 18 healthy subjects were included in this study. P-gp function was estimated by transporter activity that was inferred from a decrease in fluorescent P-gp substrate Rhodamine 123 (Rh123) and its inhibition by cyclosporine A (CsA). The P-gp efflux function in MG (FK+) patients assessed by the Kolmogorov–Smirnov (KS) statistic D was lower than in the healthy subjects (p=0.0084). However, PBMC sensitivity to FK506 in MG (FK+) patients was significantly higher compared to that of the healthy subjects (p=0.02). There was a significant correlation between the Rh123 efflux activity and PBMC sensitivity to FK506 in vitro (p=0.011). The data raise the possibility that FK506 treatment attenuated P-gp function in the PBMCs of the MG patients.

1 November 2015
Verified
Journal Article
Closed access
ENEri Nakaoka
Eri Nakaoka
STSachiko Tanaka
Sachiko Tanaka
KOKenji Onda
Kenji Onda
KSKentaro Sugiyama
Kentaro Sugiyama
俊平俊 彦 平野
俊 彦 平野

1 November 2014
Verified
Journal Article
Closed access
CSChizuko Sakai
Chizuko Sakai
MAMariko Arai
Mariko Arai
STSachiko Tanaka
Sachiko Tanaka
KOKenji Onda
Kenji Onda
KSKentaro Sugiyama
Kentaro Sugiyama
俊平俊 彦 平野
俊 彦 平野

1 December 2011
Verified
Journal Article
Closed access
EHEri Hikita
Eri Hikita
MAMariko Arai
Mariko Arai
STSachiko Tanaka
Sachiko Tanaka
KOKenji Onda
Kenji Onda
HUHiroya Utsumi
Hiroya Utsumi
俊平俊 彦 平野
俊 彦 平野